Retinoic acid prevents experimental Cushing syndrome

Marcelo Páez-Pereda, Damian Kovalovsky, Ursula Hopfner, Marily Theodoropoulou, Uberto Pagotto, Eberhard Uhl, Marco Losa, Johanna Stalla, Yvonne Grüber, Cristina Missale, Eduardo Arzt, and Günter K. Stalla

1Max Planck Institute of Psychiatry, Munich, Germany
2Laboratorio de Fisiología y Biología Molecular, Universidad de Buenos Aires and Argentine National Research Council (CONICET), Ciudad Universitaria, Buenos Aires, Argentina
3Department of Neurosurgery, University of Munich, Munich, Germany
4Department of Neurosurgery, San Raffaele Scientific Research Institute (IRCCS) San Raffaele, University of Milano, Milano, Italy
5Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy

Address correspondence to: Marcelo Páez-Pereda, Max Planck Institute of Psychiatry, Kraepelinstrasse 10, 80804 Munich, Germany.
Phone: 49-89-30622-272; Fax: 49-89-30622-605; E-mail: marcelo@mpipsykl.mpg.de.

Received for publication August 17, 2000, and accepted in revised form August 27, 2001.

Cushing syndrome is caused by an excess of adrenocorticotropic hormone (ACTH) production by neuroendocrine tumors, which subsequently results in chronic glucocorticoid excess. We found that retinoic acid inhibits the transcriptional activity of AP-1 and the orphan receptors Nur77 and Nurr1 in ACTH-secreting tumor cells. Retinoic acid treatment resulted in reduced pro-opiomelanocortin transcription and ACTH production. ACTH inhibition was also observed in human pituitary ACTH-secreting tumor cells and a small-cell lung cancer cell line, but not in normal cells. This correlated with the expression of the orphan receptor COUP-TFI, which was found in normal corticotrophs but not in pituitary Cushing tumors. COUP-TFI expression in ACTH-secreting tumor cells blocked retinoic acid action. Retinoic acid also inhibited cell proliferation and, after prolonged treatment, increased caspase-3 activity and induced cell death in ACTH-secreting cells. In adrenal cortex cells, retinoic acid inhibited corticosterone production and cell proliferation. The antiproliferative action and the inhibition of ACTH and corticosterone produced by retinoic acid were confirmed in vivo in experimental ACTH-secreting tumors in nude mice. Thus, we conclude that the effects of retinoic acid combine in vivo to reverse the endocrine alterations and symptoms observed in experimental Cushing syndrome.


Introduction

Cushing syndrome is caused by excessive glucocorticoid secretion due to adrenocorticotropic hormone (ACTH) overproduction by pituitary or lung tumors, or more rarely, to excessive glucocorticoid secretion by adrenal tumors (1–3). This glucocorticoid excess produces abnormal fat deposition, adrenal hyperplasia, thinning of the skin, hypertension, and psychological disturbances. Some inhibitors of ACTH production have been described, but they are not effective in the treatment of Cushing syndrome (4) and so, at the moment, there is no effective pharmacological therapy to control ACTH oversecretion (1–4).

ACTH biosynthesis is coordinately controlled by different transcription factors at the level of the pro-opiomelanocortin (POMC) promoter (5–7). Corticotropin-releasing hormone (CRH), the physiological stimulus for ACTH production, induces c-Fos, Nur77, and Nurr1 expression and CREB, AP-1, and Nur77/Nurr1 transcriptional activity (6–12). AP-1 has been proposed to be involved in POMC transcription (6). However, the main mediators of CRH are the nuclear orphan receptors Nur77 and Nurr1 (10–12).

Retinoic acid reduces AP-1 and Nur77 binding to their binding sites, resulting in downregulation of AP-1-responsive and Nur77-responsive genes (13–17). On the other hand, retinoic acid has shown antitumorogenic effects (18–21): it inhibits proliferation, invasion, and tumor growth in vivo and induces differentiation and apoptosis (22–25). Some of these effects are due to the inhibition of AP-1 (26). Nur77 is also critical for the antiproliferative effects of retinoic acid on lung cancer cells (27). The retinoic acid response pathways can be inhibited by the orphan receptors COUP-TF (28–30).

Based on these actions of retinoic acid on AP-1 and Nur77 and on their involvement in ACTH biosynthesis, we examined the effects of retinoic acid on ACTH-secreting tumor cells that cause Cushing syndrome.

Methods

Cell culture. AtT-20 pituitary corticotroph tumor cells (31) were cultured in DMEM with 2% FCS, NCI-N592 small-cell lung cancer cells in RPMI-1640 with 10% FCS, and y1 adrenal cortex tumor cells in Ham-F12 with 15% horse serum and 2.5% FCS. ACTH-secreting
Pituitary tumors were obtained from patients with Cushing disease. ACTH production in the tumors was confirmed as we described previously (32). Human ACTH-secreting tumor cells and rat normal pituitary cells were cultured in DMEM with 10% FCS as described previously (32). Only cultures with a vitality higher than 95% and positive responsiveness to regulatory factors were considered.

**all-trans-Retinoic acid** (Sigma Chemical Co., St. Louis, Missouri, USA) was dissolved in ethanol/DMSO as a 10-mM stock solution and handled in the dark. The same diluting mixture was used in all the in vitro experiments as control.

**Hormone measurements.** ACTH was determined by RIA as described previously (33, 34). Corticosterone was measured by RIA using a ICN Biomedical Inc. (Costa Mesa, California, USA) kit as indicated by the manufacturers.

**Transfection and reporter assays.** Cell transfection was performed with Lipofectamine (Invitrogen Life Technologies, Karlsruhe, Germany). The luciferase gene under the control of 770 bp of the rat POMC promoter includes all the necessary sequences for the expression and regulation of POMC in pituitary cells in vivo (35). The AP-1-LUC construct contains seven repeats of the AP-1 responsive sequence (Stratagene, La Jolla, California, USA).

Figure 1
Retinoic acid inhibits NurRE-directed POMC transcription. AtT-20 cells were transfected with AP-1-LUC (a), NurRE-LUC (b), NBRE-LUC (c), CRE-LUC (d), GRE-LUC (e), POMC-LUC (f), or POMC-mut-NurRE-LUC (g) or cotransfected with POMC-LUC and COUP-TFI expression vector or control vector (h), and treated with 10 nM retinoic acid (RA), 100 nM CRH, 100 nM dexamethasone (Dex), or 5 µM forskolin (Forsk) or their combinations, as indicated. After a 6-hour treatment, luciferase activity was measured and normalized as described in Methods. Values indicate the mean ± SE of luciferase-to-β-galactosidase ratio of one representative experiment out of three, each of them with triplicates of each treatment. *P < 0.01 compared with the corresponding basal values, **P < 0.01 compared with CRH or forskolin stimulation, determined by ANOVA in combination with the Scheffé test. Similar results were obtained after a 24-hour treatment with retinoic acid.

Figure 2
Retinoic acid inhibits ACTH production. AtT-20 cells were treated for 2 or 24 hours with 1 or 10 nM retinoic acid, 100 nM CRH, or 1, 10, or 100 nM dexamethasone (Dex), or their combinations as indicated. ACTH was measured in the supernatants by RIA. Averages of four wells per treatment and SEs from one representative experiment out of three are shown. *P < 0.01 compared with the basal values, **P < 0.01 compared with CRH stimulation, determined by ANOVA in combination with the Scheffé test.
Retinoic acid specifically inhibits ACTH production in human neuroendocrine tumors. (a) Human pituitary adenoma cells from eight patients with Cushing disease were treated with 10 nM or 100 nM retinoic acid (RA) for 24 hours, and ACTH was measured by RIA in the supernatants. Values at the top represent the basal ACTH production of each tumor, and the bars indicate percentages of these values after retinoic acid treatment. (b) NCI-N-592 small-cell lung cancer cells were treated with retinoic acid. After 24 hours, ACTH was measured in the supernatants. (c–e) Normal rat pituitary cells were treated for 24 hours with retinoic acid (RA), 5 μM forskolin (Forsk), 10 nM hydrocortisone (HC), 100 nM thyrotropin-releasing hormone (TRH), 1 μM bromocriptine (BrCr), 100 nM growth hormone-releasing hormone (GHRH), or 100 nM octreotide (Oct). Supernatants were collected and ACTH (c), prolactin (d), and growth hormone (GH) (e) were measured by RIA. Averages of four wells per treatment and the corresponding SEs are shown. *P < 0.001 compared with the corresponding basal values, **P < 0.01 compared with the stimulated values, determined by ANOVA in combination with the Scheffé test. b–e are representative of three independent experiments. (f) COUP-TFI expression was detected in normal human pituitary (n = 3) by immunoperoxidase staining (diaminobenzidine brown color). Inset: negative control. (g) Double immunohistochemistry for COUP-TFI (brown color, filled arrows) and ACTH (vector red color, open arrows). (h) COUP-TFI immunohistochemistry in Cushing adenomas was negative (n = 7).
Laboratories, Burlingame, California, USA). ACTH was detected with a mouse mAb (Dako Diagnostika, Hamburg, Germany) in combination with anti–mouse IgG and mouse alkaline phosphatase (AP)–anti-AP complex (Sigma, Deisenhofen, Germany) with vector red, according to the manufacturer’s instructions.

Cell proliferation and viability. ^{3}H-thymidine (0.1 μCi/ml) was added to the cultures, and its incorporation was measured as described previously (33). A WST-1 assay (Roche Molecular Biochemicals, Basel, Switzerland) was also used to measure cell proliferation and cell viability following the manufacturer’s instructions (34). Both methods produced similar results and were validated by total cell count. Acridine orange–ethidium bromide staining was used to rule out toxic effects.

Colony formation. Anchorage-independent colony formation was determined as we described previously (34, 38). The cells were treated for 24 hours, suspended in 0.3% melted agar, and plated on 0.5% agar. The cultures were incubated for 20 days and stained with dimethylthiazol-diphenyltetrazolium (MTT) to demonstrate the presence of viable cells under all treatments at the end of the experiment.

Annexin staining. Cells were stained with 1 mg/ml Annexin V-FITC (MedSystems Diagnostics GmbH, Vienna, Austria) for 10 minutes following standard procedures.

Caspase activity measurement. Caspase-3 activity (39) was measured by the proteolytic release of a chromogen from a specific caspase-3 substrate following the manufacturer’s instructions (R&D Systems Inc., Minneapolis, Minnesota, USA). The chromogen was quantified by an ELISA plate reader at 405 nm. The results were normalized to equal amounts of living cells counted by acridine orange–ethidium bromide staining.

Tumor formation and in vivo treatments. ACTH-secreting experimental tumors were formed by injecting AtT-20 cells into a subdermal pouch in BALB/c AnN Crl-nu BR nude mice (31). To evaluate retinoic acid effects on tumor formation, cells that had been treated with retinoic acid for 3 hours in vitro were trypsinized, checked for vitality, and injected into nude mice. Tumor formation was monitored after 2 and 5 weeks. In a separate set of experiments, mice with 2-week-old tumors were treated with intraperitoneal injections of 10 mg/kg retinoic acid dissolved in peanut oil. The treatment was repeated every 4 days for 3 weeks. The tumor volume was measured as we described previously (38). Blood samples were collected by heart puncture from halothane-anesthetized animals. Histological examination was performed by hematoxylin-eosin staining of shock-frozen tissues. All animal experiments were performed in accordance with institutional regulations of animal care.

Statistical analysis. Statistics were performed using one-factor ANOVA in combination with the Scheffé test.

Results
Retinoic acid effects on ACTH-secreting cells. Basal and forskolin-stimulated AP-1 transcriptional activity were inhibited by retinoic acid in AtT-20 cells after a 6-hour treatment (Figure 1a). Forskolin-stimulated NurRE- and NBRE-directed transcription, which depend on Nur77 and NurR1 dimers or monomers, respectively, were also inhibited by retinoic acid (Figure 1, b and c).
Moreover, retinoic acid inhibited the complete POMC promoter after 6 hours under basal conditions and forskolin or CRH stimulation (Figure 1f). Using a POMC promoter with a mutant NurRE, which is less responsive to forskolin (10–12), we observed that retinoic acid effect was abolished (Figure 1g). Similar results were obtained with all the constructs after a 24-hour retinoic acid treatment (not shown). These results demonstrate that the inhibition of the POMC promoter produced by retinoic acid is mediated by Nur77/Nurr1. The expression of c-Fos and Ptx-1 detected by Northern blot analysis was not affected, demonstrating that retinoic acid does not produce a general inhibition of transcription (not shown). Moreover, the transcriptional activities of the glucocorticoid receptor (GR) and CREB, detected by MTV-LUC and CRE-LUC reporters, respectively, were not affected by retinoic acid under basal or stimulated conditions, demonstrating that the inhibition of AP-1–directed and Nur77/Nurr1–directed transcription is specific (Figure 1, d and e). The retinoic acid inhibition of the POMC-LUC reporter activity was blocked by COUP-TFI expression (Figure 1h). Retinoic acid inhibited not only reporter constructs but also the endogenous ACTH production, which was only observed after 24 hours, suggesting that retinoic acid affects biosynthesis but not ACTH liberation (Figure 2). The inhibition of ACTH produced by dexamethasone was not affected by retinoic acid, and the combined effect of submaximal doses of both substances was additive (Figure 2), in agreement with the effects on POMC transcription (Figure 1f). This suggests that there is no interplay between retinoic acid and the physiological glucocorticoid-mediated inhibition of ACTH. Toxic or proliferative effects after a 6- or 24-hour treatment were ruled out by annexin V staining (see Figure 4), acridine orange–ethidium bromide staining, and WST-1 assay (not shown). These results demonstrate that retinoic acid specifically inhibits ACTH production in ACTH-secreting tumor cells. We found that COUP-TFI, which can block retinoic acid action in ACTH-secreting tumor cells (Figure 1h), is expressed only in the normal pituitary (n = 3) where it colocalizes with ACTH immunoreactivity, but it is not expressed in Cushing pituitary tumors (n = 7) (Figure 3, f–h). The same expression pattern of COUP-TFI was observed using RT-PCR (not shown).

To evaluate whether retinoic acid would be of profit for human patients we studied the effect on Cushing tumors in primary culture. We observed that 10 nM retinoic acid inhibited ACTH production after a 24-hour treatment in six out of eight tumors (Figure 3a). The two other tumors only showed an inhibitory response with 100 nM retinoic acid (Figure 3a; tumor numbers 2 and 6). We also studied the small-cell lung cancer cell line NCI-N592 and found that retinoic acid inhibited ACTH production (Figure 3b). This demonstrates that retinoic acid affects ACTH biosynthesis in different neuroendocrine tumor types. We found that retinoic acid does not affect ACTH, prolactin, or growth hormone production in rat normal pituitary cells, which were responsive to regulatory factors (Figures 3, c–e). Therefore, we conclude that retinoic acid specifically inhibits ACTH production in ACTH-secreting tumor cells. We found that COUP-TFI, which can block retinoic acid action in ACTH-secreting tumor cells (Figure 1h), is expressed only in the normal pituitary (n = 3) where it colocalizes with ACTH immunoreactivity, but it is not expressed in Cushing pituitary tumors (n = 7) (Figure 3, f–h). The same expression pattern of COUP-TFI was observed using RT-PCR (not shown).

**Figure 5**
Retinoic acid inhibits corticosterone production and adrenal cortex cell proliferation. (a) y1 adrenal cortex cells were treated for 24 hours with retinoic acid (RA) or 5 μM forskolin (Forsk) as indicated. Supernatants were collected and corticosterone was measured by RIA. (b) y1 cells were treated for 3 days with retinoic acid (RA). Proliferation was measured by WST-1 assay. In a and b averages of four wells per treatment and SEs are shown. *P < 0.001 compared with the forskolin stimulation, determined by ANOVA in combination with the Scheffé test. (c) y1 cells were treated for 24 hours with 10 nM retinoic acid, seeded in soft agar, stained with MTT, and photographed after 20 days. The control shows colonies composed of more than 300 cells. Retinoic acid–treated cells formed colonies composed of less than ten viable cells. These results are representative of three independent experiments with triplicates of each treatment.
were injected intraperitoneally with 10 mg/kg retinoic acid or vehicle (and analyzed by hematoxylin-eosin staining. Adrenals (and skin) were treated with vehicle (10 nM retinoic acid) for 3 hours and then injected into nude mice. (a and b) Representative examples of the mice after 5 weeks (n = 10 in each treatment). Notice the 12-mm-diameter tumor developed by vehicle-treated cells (a). Thinning of the skin was consistently observed in mice with tumors (a). (c–j) Mice with tumors were injected intraperitoneally with 10 mg/kg retinoic acid or vehicle (n = 5 in each experiment) every 4 days for 3 weeks. At the end of the treatment the tumors (e and f, arrows indicate areas of necrosis), adrenal glands (e–g), and skin samples (h–j) were shock-frozen and analyzed by hematoxylin-eosin staining. Adrenals (e) and skin (h) from vehicle-treated mice without tumors. Tumor (c), adrenals (f), and skin (i) from vehicle-treated mice with tumors. Tumor (d), adrenals (g), and skin (j) from retinoic acid–treated mice with tumors. These results are representative of two independent experiments.

To further characterize the actions of retinoic acid we measured cell proliferation. We observed an inhibition of AtT-20 cell proliferation measured by 3H-thymidine incorporation after 3 days of retinoic acid treatment (Figure 4a). Similar results were obtained by the WST-1 assay, and total cell count (not shown) and acridine orange–ethidium bromide staining showed no differences, indicating that there was no cell death. A 24-hour treatment with retinoic acid also inhibited anchorage-independent colony formation (Figure 4b), indicating that retinoic acid affects the intrinsic mechanisms controlling cell proliferation.

Retinoic acid did not induce apoptosis after 6- or 24-hour treatments as evidenced by annexin V staining (Figure 4, c–h). We then studied the induction of apoptosis in AtT-20 cells after prolonged retinoic acid treatment by measuring caspase-3, a key mediator of the proteolytic cascade leading to apoptosis (39). We observed a marked increase in caspase-3 activity after 5 days of treatment (Figure 4i). A subsequent reduction in the number of viable cells was observed after 7 days (Figure 4i). The increase in caspase-3 after 3 days could partially explain the reduction in thymidine incorporation (Figure 4a), although no cell death was observed at that time. These data demonstrate that prolonged retinoic acid treatment induces apoptosis and therefore reduces the number of viable AtT-20 cells.

Effects of retinoic acid on adrenal cortex cells. We studied the effects of retinoic acid on corticosterone production by adrenal cortex cells. Retinoic acid did not change the basal corticosterone production in y1 adrenal cortex cells after a 24-hour treatment, but partially inhibited the stimulation produced by forskolin, which mimics ACTH effects (Figure 5a). We ruled out toxic or proliferative effects by acridine orange–ethidium bromide staining and WST-1 assay. We also found that retinoic acid did not have any effect on the basal cell proliferation but inhibited the stimulation produced by forskolin after 3 days (Figure 5b). No differences in cell viability were observed after prolonged treatment (not shown). Retinoic acid also inhibited the anchorage-independent colony formation (Figure 5c). Therefore, we conclude that retinoic acid inhibits the forskolin-stimulated corticosterone secretion and cell proliferation in adrenal cortex cells.

In vivo effects of retinoic acid. To test whether retinoic acid affects the ability of ACTH-secreting cells to form tumors in vivo we treated AtT-20 cells for 3 hours with retinoic acid and then injected them into nude mice. After 2 weeks, all the mice injected with vehicle-treated cells developed tumors, whereas no tumors were observed in the mice injected with retinoic acid–treated cells. After 5 weeks all mice injected with vehicle-treated cells had a marked thinning of the skin, enlarged adrenal glands, and adrenal cortex hyperplasia (Figure 6, a and f, as compared with Figure 6e and Figure 7b). The plasma levels of ACTH and corticosterone were greatly elevated (Figure 7, c and d). These symptoms mimic Cushing syndrome in humans. Only 20% of the mice injected with retinoic acid–treated cells developed small tumors after 5 weeks. The mice injected with retinoic acid–treated cells that did not develop tumors did not show any noticeable changes (Figure 6b). Therefore, we deduce that retinoic acid pretreatment reduces the ability of ACTH-secreting cells to form tumors in vivo.

To test the efficacy of retinoic acid treatment on tumor growth after implantation, we administered retinoic acid in vivo to mice that already had experimental ACTH-secreting tumors. Specifically, we injected mice that had 2-week-old tumors with 10 mg/kg retinoic acid intraperitoneally every 4 days for 3 weeks.
The tumor volume was monitored throughout the treatment. Retinoic acid completely blocked the growth of corticotroph tumors (Figure 7a). Histological examination showed that the tumors under retinoic acid treatment had signs of focal cell death (Figure 6, d as compared with c). These results demonstrate that in vivo treatment with retinoic acid inhibits corticotroph tumor growth and supports our in vitro findings on cell proliferation and apoptosis. We found that retinoic acid partially but significantly reduces plasma ACTH levels (Figure 7c). Corticosterone was reduced by retinoic acid to levels similar to the control (Figure 7d). Therefore, retinoic acid administered in vivo reverses the endocrine alterations produced by corticotroph tumors. This is in agreement with the effects we observed in vitro in ACTH- and corticosterone-secreting cells. Adrenal hyperplasia induced by the tumors was prevented by retinoic acid (Figure 7b). This was also observed in histological sections (Figure 6, g as compared with f). The dermal atrophy induced by the ACTH-secreting tumors was also prevented by retinoic acid (Figure 6, j as compared with i). All these results indicate that retinoic acid effectively reduces in vivo symptoms of Cushing syndrome.

Discussion
We found that retinoic acid inhibits the AP-1 and Nur77/Nurr1 transcriptional activities in ACTH-secreting cells. These results are in line with previous studies on other cells that demonstrate that retinoic acid can inhibit AP-1–dependent genes (13–16) and also represses Nur77 transactivation activity (17). We further demonstrate that retinoic acid inhibits POMC transcription, which is controlled by AP-1, Nur77, and Nurr1 (5–12). Moreover, we demonstrate that a mutation in the Nur77/Nurr1–binding site NurRE is sufficient to abolish the inhibition produced by retinoic acid. This inhibition is similar to the inhibition of POMC transcription produced by mutation of the NurRE or AP-1–binding sites (5). The stimulation of POMC by CRH, which is mediated by Nur77 and could also involve AP-1, was inhibited by retinoic acid. These results are also in agreement with the reduction of the CRH-stimulated POMC transcription produced by the mutation of the NurRE or AP-1–binding sites (6, 10). The NBRE-binding site, which, as previously shown, is less sensitive to stimulation, is slightly inhibited by retinoic acid. Therefore, it is less relevant than the NurRE site for retinoic acid effects. On the other hand, factors that are important for the function of corticotroph cells such as CREB, GR, and Ptx-1 were not affected by retinoic acid, demonstrating the specificity of the effects we observed. Our results were confirmed by the fact that the endogenous production of ACTH was reduced by retinoic acid in AtT-20 cells. ACTH inhibition was observed in tumor cells with pituitary or lung origin, demonstrating that the ACTH biosynthesis is affected by retinoic acid in different tumor types. However, ACTH inhibition was observed only in tumor cells but not in normal pituitary cells. Interestingly, this effect is different from the one of glucocorticoids, which efficiently inhibit ACTH production in normal corticotroph cells but have only a partial effect on tumors. This partial insensitivity to glucocorticoids makes Cushing tumors resistant to the physiological negative feedback. Therefore, retinoic acid does not constitute a physiological feedback mechanism, but the profile of retinoic acid effects makes it even more suitable as a possible therapy for Cushing syndrome. We found that COUP-TFI, which inhibits the retinoic acid response pathways (28–30), can also block the effects of retinoic acid in ACTH-secreting tumor cells. Moreover, COUP-TFI is only expressed in normal ACTH-secreting cells but not in pituitary Cushing tumors. This expression pattern may provide an explanation for the differential effects of retinoic acid on tumor cells. Other genes that have been found to be differentially expressed in pituitary tumors might also be involved in the differential action of retinoic acid (40).

Figure 7
Retinoic acid inhibits tumor growth and endocrine alterations. (a) Mice with 2-week-old tumors formed with untreated AtT-20 cells were injected intraperitoneally with 10 mg/kg retinoic acid (open symbols, RA) or vehicle (filled symbols) every 4 days for 3 weeks. Tumor volume was monitored during this period. Results show the increase in percentage over the initial tumor volume. Each curve represents a single tumor. (b) At the end of the treatment the weight of the adrenal glands was measured in mice without tumors (control, n = 5) and in mice with tumors with or without retinoic acid treatment (RA) as indicated (n = 5 for each treatment). (c and d) At the end of the treatment blood was collected and ACTH and corticosterone were measured by RIA. Values indicate the mean ± SE of one experiment. *P < 0.01, as determined by ANOVA in combination with the Scheffé test. The results are representative of two independent experiments.
We found that retinoic acid inhibits ACTH- and corticosterone-secreting cell proliferation. At least some of the antiproliferative effects of retinoic acid are due to the inhibition of AP-1–dependent genes (26). Interestingly, the balance between Nur77 and COUP-TF is also critical for the antiproliferative effects of retinoic acid in lung cancer (27). Due to the fact that retinoic acid has pleiotropic effects, we cannot exclude the possibility that other pathways independent of AP-1 or Nur77/Nurr1 could contribute to the antiproliferative effects. However, the end effect of retinoic acid on ACTH- and corticosterone-secreting tumor cells is antiproliferative in vivo and in vitro. Moreover, the induction of caspase-3 activity and the subsequent reduction in cell viability, together with the induction of focal cell death in vivo, contribute to the antitumorigenic effect in ACTH-secreting cells. The effects of retinoic acid in vitro are paralleled by the effects we observed in vivo, and furthermore they cooperate to suppress the symptoms of Cushing syndrome. Retinoic acid inhibition of proliferation and induction of apoptosis/cell death combine to reduce the tumor mass. The inhibition of ACTH and corticosterone secretion together with the reduction of tumor mass cooperate to reverse the endocrine alterations produced by Cushing tumors in vivo, resulting in the reversal of such symptoms of Cushing syndrome as adrenal hyperplasia and skin atrophy. The reduction of adrenal hyperplasia could be due to the reduction in ACTH levels as well as to the direct inhibition of adrenal cell proliferation. The reversion of skin atrophy is in line with previous studies that show that retinoic acid can reverse the changes produced by glucocorticoids on dermal connective tissue (41). Therefore, retinoic acid could reverse the symptoms in the skin by a direct mechanism that may concur with the hormonal inhibition and the antitumorigenic effects.

Clinical studies have shown that retinoids are effective in the treatment of acute promyelocytic leukemia and squamous cell carcinomas of the skin and cervix and in the chemoprevention of lung cancer (18–21). The doses of retinoic acid used in our study are within the dose range currently used to treat patients with various neoplasias (18–21). On the other hand, retinoic acid has been shown to stimulate growth hormone in vitro in the lacto-somatotrophic tumor cell line GH3 (42). In our study we have not detected changes in growth hormone or prolactin production in normal pituitary cells. Therefore, the differential effect of retinoic acid on ACTH could, hypothetically, represent a therapeutic advantage. The immunostimulation produced by retinoic acid (43) could also be of benefit for Cushing patients who show some impaired immune functions due to glucocorticoid excess. These characteristics of retinoic acid further support the possibility of a successful treatment of ACTH-secreting tumors in human patients, for whom there is no effective pharmacological therapy.

To summarize, we describe the specific inhibitory effects of retinoic acid on ACTH biosynthesis at the level of AP-1 and Nur77/Nurr1 transcriptional activities and POMC transcription in ACTH-secreting tumor cells. We demonstrate that retinoic acid reduces cell proliferation and viability. These results are also supported by the inhibition of hormone production and tumor growth observed in vivo. All these results indicate that retinoic acid might be an interesting therapeutc option to inhibit ACTH, cortisol, and tumor growth in Cushing syndrome.

Acknowledgments
We thank M. Low (Vollum Institute, Portland, Oregon, USA) for the POMC-LUC construct, J. Drouin (University of Montréal, Quebec, Canada) for the NurRE and NBRE reporters and the POMC promoter with a mutated NurRE site, and M. Tsai (Baylor College of Medicine, Houston, Texas, USA) for the COUP-TFI expression vector. We also thank W. Bollag (Roche, Basel, Switzerland) and O. Almeida (Max Planck Institute of Psychiatry, Munich, Germany) for comments on the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft (Sta 285/7-3) and the Volkswagen Foundation (I/76 803).